Amar E, Kobelinsky M, Khoury R, Sarkis P, Bouyer I, Dauphin A, Delmas V, Boccon-Gibod L
Clinique urologique, Hôpital Bichat, Paris.
Prog Urol. 1993 Dec;3(6):971-8.
As already reported, PGE1 induces a valid erection, when administered intracavernously, without causing prolonged erection or general side effects. We have tested PGE1 (< 20 micrograms) in 180 patients suffering from organic erectile impotence, a complete erection was observed in 130 (72.2%), while incomplete erection was noted in 37 (20.5%). In both groups (92.7%) erection was sufficient for sexual intercourse. Among the best results, 41 patients had previously received high doses intracavernous injection of papaverine, without any benefit, and 15 patients have cavernosal venous leakage documented by cavernosometry and cavernosography before prostaglandin E1 test. Tumescence without rigidity was noted in 13 (7.2%). Of these 167 patients, 95 entered an autoinjection protocol for treatment of erectile dysfunction, using special device. In our series neither systemic reaction nor prolonged erection occurred. No fibrosis of cavernous tissue or scar formation was observed after up to 125 injections. However, 19 patients (10.5%) reported burning sensations during the entire period of erection and one patient (0.5%) had an haematoma at the site of the injection. PGE1 is effective in inducing artificial penile erection and it has a role in the diagnosis and treatment of erectile dysfunction, it is considered to be a more suitable agent than other vasoactive drugs.
如前所述,经海绵体内给药时,前列腺素E1可诱发有效的勃起,且不会导致持续性勃起或产生全身性副作用。我们对180例器质性勃起功能障碍患者进行了前列腺素E1(<20微克)测试,其中130例(72.2%)观察到完全勃起,37例(20.5%)为不完全勃起。两组中(92.7%)的勃起程度足以进行性交。在效果最佳的患者中,41例之前曾接受过高剂量的罂粟碱海绵体内注射,但未获任何益处,15例在前列腺素E1测试前经海绵体测压和海绵体造影证实存在海绵体静脉漏。有13例(7.2%)出现了无硬度的肿胀。在这167例患者中,95例使用特殊装置进入了用于治疗勃起功能障碍的自我注射方案。在我们的系列研究中,既未发生全身反应,也未出现持续性勃起。在进行多达125次注射后,未观察到海绵体组织纤维化或瘢痕形成。然而,19例患者(10.5%)在整个勃起期间均报告有烧灼感,1例患者(0.5%)在注射部位出现血肿。前列腺素E1在诱发人工阴茎勃起方面有效,并且在勃起功能障碍的诊断和治疗中具有作用,它被认为是比其他血管活性药物更合适的药物。